Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1996 Jul;51(7):750–755. doi: 10.1136/thx.51.7.750

The role of recombinant human DNase in the treatment of patients with cystic fibrosis: many promises, more problems.

M S Zach 1
PMCID: PMC472501  PMID: 8882085

Full text

PDF
750

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARMSTRONG J. B., WHITE J. C. Liquefaction of viscous purulent exudates by deoxyribonuclease. Lancet. 1950 Dec 9;2(6641):739–742. doi: 10.1016/s0140-6736(50)91676-x. [DOI] [PubMed] [Google Scholar]
  2. Aitken M. L., Burke W., McDonald G., Shak S., Montgomery A. B., Smith A. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study. JAMA. 1992 Apr 8;267(14):1947–1951. [PubMed] [Google Scholar]
  3. Balough K., McCubbin M., Weinberger M., Smits W., Ahrens R., Fick R. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol. 1995 Aug;20(2):63–70. doi: 10.1002/ppul.1950200203. [DOI] [PubMed] [Google Scholar]
  4. Bataillon V., Lhermitte M., Lafitte J. J., Pommery J., Roussel P. The binding of amikacin to macromolecules from the sputum of patients suffering from respiratory diseases. J Antimicrob Chemother. 1992 May;29(5):499–508. doi: 10.1093/jac/29.5.499. [DOI] [PubMed] [Google Scholar]
  5. Brandt T., Breitenstein S., von der Hardt H., Tümmler B. DNA concentration and length in sputum of patients with cystic fibrosis during inhalation with recombinant human DNase. Thorax. 1995 Aug;50(8):880–882. doi: 10.1136/thx.50.8.880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bryson H. M., Sorkin E. M. Dornase alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis. Drugs. 1994 Dec;48(6):894–906. doi: 10.2165/00003495-199448060-00006. [DOI] [PubMed] [Google Scholar]
  7. CHERNICK W. S., BARBERO G. J. Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiectasis. Pediatrics. 1959 Nov;24:739–745. [PubMed] [Google Scholar]
  8. CHERNICK W. S., BARBERO G. J., EICHEL H. J. In-vitro evaluation of effect of enzymes on tracheobronchial secretions from patients withcystic fibrosis. Pediatrics. 1961 Apr;27:589–596. [PubMed] [Google Scholar]
  9. Dasgupta B., Tomkiewicz R. P., Boyd W. A., Brown N. E., King M. Effects of combined treatment with rhDNase and airflow oscillations on spinnability of cystic fibrosis sputum in vitro. Pediatr Pulmonol. 1995 Aug;20(2):78–82. doi: 10.1002/ppul.1950200205. [DOI] [PubMed] [Google Scholar]
  10. Davis S. D., Bruns W. T. Effects of sputum from patients with cystic fibrosis on the activity in vitro of 5 antimicrobial drugs on Pseudomonas aeruginosa. Am Rev Respir Dis. 1978 Jan;117(1):176–178. doi: 10.1164/arrd.1978.117.1.176. [DOI] [PubMed] [Google Scholar]
  11. ELMES P. C., WHITE J. C. Deoxyribonuclease in the treatment of purulent bronchitis. Thorax. 1953 Dec;8(4):295–300. doi: 10.1136/thx.8.4.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. FitzSimmons S. C. The changing epidemiology of cystic fibrosis. J Pediatr. 1993 Jan;122(1):1–9. doi: 10.1016/s0022-3476(05)83478-x. [DOI] [PubMed] [Google Scholar]
  13. Fuchs H. J., Borowitz D. S., Christiansen D. H., Morris E. M., Nash M. L., Ramsey B. W., Rosenstein B. J., Smith A. L., Wohl M. E. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994 Sep 8;331(10):637–642. doi: 10.1056/NEJM199409083311003. [DOI] [PubMed] [Google Scholar]
  14. Girod de Bentzmann S., Pierrot D., Fuchey C., Zahm J. M., Morançais J. L., Puchelle E. Distearoyl phosphatidylglycerol liposomes improve surface and transport properties of CF mucus. Eur Respir J. 1993 Sep;6(8):1156–1161. [PubMed] [Google Scholar]
  15. Hodson M. E., Shah P. L. DNase trials in cystic fibrosis. Eur Respir J. 1995 Oct;8(10):1786–1791. doi: 10.1183/09031936.95.08101786. [DOI] [PubMed] [Google Scholar]
  16. Hubbard R. C., McElvaney N. G., Birrer P., Shak S., Robinson W. W., Jolley C., Wu M., Chernick M. S., Crystal R. G. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med. 1992 Mar 19;326(12):812–815. doi: 10.1056/NEJM199203193261207. [DOI] [PubMed] [Google Scholar]
  17. King M., Zahm J. M., Pierrot D., Vaquez-Girod S., Puchelle E. The role of mucus gel viscosity, spinnability, and adhesive properties in clearance by simulated cough. Biorheology. 1989;26(4):737–745. doi: 10.3233/bir-1989-26406. [DOI] [PubMed] [Google Scholar]
  18. Konstan M. W., Hilliard K. A., Norvell T. M., Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med. 1994 Aug;150(2):448–454. doi: 10.1164/ajrccm.150.2.8049828. [DOI] [PubMed] [Google Scholar]
  19. Lethem M. I., James S. L., Marriott C., Burke J. F. The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum. Eur Respir J. 1990 Jan;3(1):19–23. [PubMed] [Google Scholar]
  20. Lethem M. I., James S. L., Marriott C. The role of mucous glycoproteins in the rheologic properties of cystic fibrosis sputum. Am Rev Respir Dis. 1990 Nov;142(5):1053–1058. doi: 10.1164/ajrccm/142.5.1053. [DOI] [PubMed] [Google Scholar]
  21. Levy J., Smith A. L., Kenny M. A., Ramsey B., Schoenknecht F. D. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum. J Infect Dis. 1983 Dec;148(6):1069–1076. doi: 10.1093/infdis/148.6.1069. [DOI] [PubMed] [Google Scholar]
  22. Lieberman J. Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis. JAMA. 1968 Jul 29;205(5):312–313. [PubMed] [Google Scholar]
  23. Lieberman J. Measurement of sputum viscosity in a cone-plate viscometer. II. An evaluation of mucolytic agents in vitro. Am Rev Respir Dis. 1968 Apr;97(4):662–672. doi: 10.1164/arrd.1968.97.4.662. [DOI] [PubMed] [Google Scholar]
  24. MATTHEWS L. W., SPECTOR S., LEMM J., POTTER J. L. STUDIES ON PULMONARY SECRETIONS. I. THE OVER-ALL CHEMICAL COMPOSITION OF PULMONARY SECRETIONS FROM PATIENTS WITH CYSTIC FIBROSIS, BRONCHIECTASIS, AND LARYNGECTOMY. Am Rev Respir Dis. 1963 Aug;88:199–204. doi: 10.1164/arrd.1963.88.2.199. [DOI] [PubMed] [Google Scholar]
  25. Mendelman P. M., Smith A. L., Levy J., Weber A., Ramsey B., Davis R. L. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis. 1985 Oct;132(4):761–765. doi: 10.1164/arrd.1985.132.4.761. [DOI] [PubMed] [Google Scholar]
  26. Oberwaldner B., Theissl B., Rucker A., Zach M. S. Chest physiotherapy in hospitalized patients with cystic fibrosis: a study of lung function effects and sputum production. Eur Respir J. 1991 Feb;4(2):152–158. [PubMed] [Google Scholar]
  27. Picot R., Das I., Reid L. Pus, deoxyribonucleic acid, and sputum viscosity. Thorax. 1978 Apr;33(2):235–242. doi: 10.1136/thx.33.2.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Potter J. L., Matthews L. W., Spector S., Lemm J. Complex formation between basic antibiotics and deoxyribonucleic acid in human pulmonary secretions. Pediatrics. 1965 Nov;36(5):714–720. [PubMed] [Google Scholar]
  29. Power C., O'Connor C. M., MacFarlane D., O'Mahoney S., Gaffney K., Hayes J., FitzGerald M. X. Neutrophil collagenase in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med. 1994 Sep;150(3):818–822. doi: 10.1164/ajrccm.150.3.8087357. [DOI] [PubMed] [Google Scholar]
  30. Puchelle E., Zahm J. M., Quemada D. Rheological properties controlling mucociliary frequency and respiratory mucus transport. Biorheology. 1987;24(6):557–563. doi: 10.3233/bir-1987-24606. [DOI] [PubMed] [Google Scholar]
  31. Ramphal R., Lhermitte M., Filliat M., Roussel P. The binding of anti-pseudomonal antibiotics to macromolecules from cystic fibrosis sputum. J Antimicrob Chemother. 1988 Oct;22(4):483–490. doi: 10.1093/jac/22.4.483. [DOI] [PubMed] [Google Scholar]
  32. Ramsey B. W., Astley S. J., Aitken M. L., Burke W., Colin A. A., Dorkin H. L., Eisenberg J. D., Gibson R. L., Harwood I. R., Schidlow D. V. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis. 1993 Jul;148(1):145–151. doi: 10.1164/ajrccm/148.1.145. [DOI] [PubMed] [Google Scholar]
  33. Ranasinha C., Assoufi B., Shak S., Christiansen D., Fuchs H., Empey D., Geddes D., Hodson M. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet. 1993 Jul 24;342(8865):199–202. doi: 10.1016/0140-6736(93)92297-7. [DOI] [PubMed] [Google Scholar]
  34. Range S. P., Knox A. J. rhDNase in cystic fibrosis. Thorax. 1995 Apr;50(4):321–322. doi: 10.1136/thx.50.4.321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Regelmann W. E., Siefferman C. M., Herron J. M., Elliott G. R., Clawson C. C., Gray B. H. Sputum peroxidase activity correlates with the severity of lung disease in cystic fibrosis. Pediatr Pulmonol. 1995 Jan;19(1):1–9. doi: 10.1002/ppul.1950190102. [DOI] [PubMed] [Google Scholar]
  36. SALOMON A., HERCHFUS J. A., SEGAL M. S. Aerosols of pancreatic dornase in bronchopulmonary disease. Ann Allergy. 1954 Jan-Feb;12(1):71–77. [PubMed] [Google Scholar]
  37. SPIER R., WITEBSKY E., PAINE J. R. Aerosolized pancreatic dornase and antibiotics in pulmonary infections: use in patients with postoperative and nonoperative infections. JAMA. 1961 Dec 2;178:878–886. doi: 10.1001/jama.1961.03040480008003. [DOI] [PubMed] [Google Scholar]
  38. Shah P. L., Scott S. F., Fuchs H. J., Geddes D. M., Hodson M. E. Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I. Thorax. 1995 Apr;50(4):333–338. doi: 10.1136/thx.50.4.333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Shah P. L., Scott S. F., Geddes D. M., Hodson M. E. Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respir Med. 1995 Aug;89(7):499–502. doi: 10.1016/0954-6111(95)90126-4. [DOI] [PubMed] [Google Scholar]
  40. Shak S., Capon D. J., Hellmiss R., Marsters S. A., Baker C. L. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci U S A. 1990 Dec;87(23):9188–9192. doi: 10.1073/pnas.87.23.9188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Smith A. L., Redding G., Doershuk C., Goldmann D., Gore E., Hilman B., Marks M., Moss R., Ramsey B., Rubio T. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr. 1988 Apr;112(4):547–554. doi: 10.1016/s0022-3476(88)80165-3. [DOI] [PubMed] [Google Scholar]
  42. Zach M. S. Lung disease in cystic fibrosis--an updated concept. Pediatr Pulmonol. 1990;8(3):188–202. doi: 10.1002/ppul.1950080311. [DOI] [PubMed] [Google Scholar]
  43. Zach M. S., Oberwaldner B. Chest physiotherapy--the mechanical approach to antiinfective therapy in cystic fibrosis. Infection. 1987;15(5):381–384. doi: 10.1007/BF01647750. [DOI] [PubMed] [Google Scholar]
  44. Zahm J. M., Girod de Bentzmann S., Deneuville E., Perrot-Minnot C., Dabadie A., Pennaforte F., Roussey M., Shak S., Puchelle E. Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus. Eur Respir J. 1995 Mar;8(3):381–386. doi: 10.1183/09031936.95.08030381. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES